Download PDF
Diabetes aktuell 2018; 16(02): 56-63
DOI: 10.1055/a-0621-8419
Schwerpunkt
Diagnostik
© Georg Thieme Verlag Stuttgart · New York

Zielgerichtete Erstdiagnostik bei Typ-1-Diabetes

Abgrenzung von anderen Diabetesformen und Autoimmunsyndromen
Hannes Kalscheuer
1   Endokrinologie/Diabetologie, Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
,
Hendrik Lehnert
2   Institut für Neuroendokrinologie, Universität Lübeck
› Author Affiliations
Further Information

Publication History

Publication Date:
13 June 2018 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Der Diabetes mellitus Typ 1 nimmt weltweit zu und ist eine der häufigsten chronischen Erkrankungen im Kindesalter. Allerdings manifestiert sich ein Typ-1-Diabetes nicht selten erst im Erwachsenenalter – dann wird die eindeutige klinische Abgrenzung zum Typ-2-Diabetes mitunter schwierig. Andere Diabetesformen und Autoimmunsyndrome müssen ebenfalls berücksichtigt werden. Dieser Beitrag stellt die Möglichkeiten einer zielführenden Diagnostik zusammen.

 

  • Literatur

  • 1 World Health Organization. Global report on diabetes. 2016. www.who.int/diabetes/global-report/en/ (letzter Zugriff: 25.04.2018)
  • 2 Diabetes-Informationsdienst München.Typ-1-Diabetes: Verbreitung. www.diabetesinformationsdienst-muenchen.de/erkrankungsformen/typ-1-diabetes/verbreitung/index.html (letzter Zugriff: 25.04.2018)
  • 3 Patterson CC, Dahlquist GG, Gyurus E. et al. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005-20: a multicentre prospective registration study.. Lancet 2009; 373: 2027-2033 doi: 10.1016/S0140-6736(09)60568-7
    CrossrefGoogle Scholar
  • 4 Jones KL. Role of obesity in complicating and confusing the diagnosis and treatment of diabetes in children.. Pediatrics 2008; 121: 361-368 doi: 10.1542/peds.2007-1234
    CrossrefGoogle Scholar
  • 5 Zeitler P. Approach to the obese adolescent with new-onset diabetes.. J Clin Endocrinol Metab 2010; 95: 5163-5170 doi: 10.1210/jc.2010-0958
    CrossrefGoogle Scholar
  • 6 Thomas N, Jones S, Weedon M. et al. Classifying diabetes by type 1 genetic risk shows autoimmune diabetes cases are evenly distributed above and below 30 years of age. EASD Virtual Meeting; München 2016. Abstract 264 www.easdvirtualmeeting.org/resources/classifying-diabetes-by-type-1-genetic-risk-shows-autoimmune-diabetes-cases-are-evenly-distributed-above-and-below-30-years-of-age (letzter Zugriff: 25.04.2018)
    Google Scholar
  • 7 Maahs DM, West NA, Lawrence JM, Mayer Davis. et al. Epidemiology of type 1 diabetes.. Endocrinol Metab Clin North Am 2010; 39: 481-497 doi: 10.1016/j.ecl.2010.05.011
    CrossrefPubMedGoogle Scholar
  • 8 Davis TM, Wright AD, Mehta ZM. et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).. Diabetologia 2005; 48: 695-702 doi: 10.1007/s00125-005-1690-x
    CrossrefGoogle Scholar
  • 9 Imperatore G, Boyle JP, Thompson TJ. et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth.. Diabetes Care 2012; 35: 2515-2520 doi: 10.2337/dc12-0669
    CrossrefGoogle Scholar
  • 10 Smyth S, Heron A. Diabetes and obesity: the twin epidemics.. Nat Med 2006; 12: 75-80 doi: 10.1038/nm0106-75
    CrossrefGoogle Scholar
  • 11 Kerner W, Brückel J. Definition, Klassifikation und Diagnostik des Diabetes mellitus.. Diabetologie und Stoffwechsel 2012; 7: S84-S87 doi: 10.1055/s-0032-1325519
    Article in Thieme ConnectGoogle Scholar
  • 12 Zhang B, Kumar RB, Dai H, Feldman BJ. A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes.. Nat Med 2014; 20: 948-953 doi: 10.1038/nm.3619
    CrossrefGoogle Scholar
  • 13 Wenzlau JM, Juhl K, Yu L. et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.. Proc Natl Acad Sci U S A 2007; 104: 17040-17045 doi: 10.1073/pnas.0705894104
    CrossrefGoogle Scholar
  • 14 Neu A, Hofer SE, Karges B. et al. Ketoacidosis at diabetes onset is still frequent in children and adolescents: a multicenter analysis of 14,664 patients from 106 institutions.. Diabetes Care 2009; 32: 1647-1648 doi: 10.2337/dc09-0553
    CrossrefPubMedGoogle Scholar
  • 15 Böhm BO, Dreyer M, Fritsche A. et al. S3-Leitlinie Therapie des Typ-1-Diabetes. Deutsche Diabetes Gesellschaft, Version 1.0, September 2011. www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/AktualisierungTherapieTyp1Diabetes_1_20120319_TL.pdf (letzter Zugriff: 25.04.2018)
    Google Scholar
  • 16 Goldberg PA, Siegel MD, Sherwin RS. et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit.. Diabetes Care 2004; 27: 461-467 doi: 10.2337/diacare.27.2.461
    CrossrefGoogle Scholar
  • 17 Herold KC, Vignali DA, Cooke A. et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes.. Nat Rev Immunol 2013; 13: 243-256 doi: 10.1038/nri3422
    CrossrefGoogle Scholar
  • 18 Cordell HJ, Todd JA. Multifactorial inheritance in type 1 diabetes.. Trends Genet 1995; 11: 499-504 doi: 10.1016/S0168-9525(00)89160-X
    CrossrefGoogle Scholar
  • 19 Morran MP, Vonberg A, Khadra A, Pietropaolo M. Immunogenetics of type 1 diabetes mellitus.. Mol Aspects Med 2015; 42: 42-60 doi: 10.1016/j.mam.2014.12.004
    CrossrefPubMedGoogle Scholar
  • 20 Lampasona V, Liberati D. Islet Autoantibodies.. Curr Diab Rep 2016; 16: 53 doi: 10.1007/s11892-016-0738-2
    CrossrefGoogle Scholar
  • 21 McLaughlin KA, Richardson CC, Ravishankar A. et al. Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes.. Diabetes 2016; 65: 1690-1698 doi: 10.2337/db15-1058
    CrossrefGoogle Scholar
  • 22 Pihoker C, Gilliam LK, Hampe CS, Lemmark A. Autoantibodies in diabetes.. Diabetes 2005; 54 (02) S52-S61 doi: 10.2337/diabetes.54.suppl_2.S52
    CrossrefGoogle Scholar
  • 23 Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes.. Nature 2010; 464: 1293-1300 doi: 10.1038/nature08933
    CrossrefGoogle Scholar
  • 24 Visperas A, Vignali DA. Are regulatory T cells defective in type 1 diabetes and can we fix them?. J Immunol 2016; 197: 3762-3770 10.4049/jimmunol.1601118
    CrossrefGoogle Scholar
  • 25 Rodriguez-Calvo T, Sabouri S, Anquetil F, von Herrath MG. The viral paradigm in type 1 diabetes: Who are the main suspects?. Autoimmun Rev 2016; 15: 964-969 doi: 10.1016/j.autrev.2016.07.019
    CrossrefGoogle Scholar
  • 26 Amiel SA, Pursey N, Higgins B. et al. Diagnosis and management of type 1 diabetes in adults: summary of updated NICE guidance.. BMJ 2015; 351: h4188 doi: 10.1136/bmj.h4188
    Google Scholar
  • 27 Fourlanos S, Dotta F, Greenbaum CJ. et al. Latent autoimmune diabetes in adults (LADA) should be less latent.. Diabetologia 2005; 48: 2206-2212 10.1007/s00125-005-1960-7
    CrossrefPubMedGoogle Scholar
  • 28 Laugesen E, Ostergaard JA, Leslie RD. Latent autoimmune diabetes of the adult: current knowledge and uncertainty.. Diabet Med 2015; 32: 843-852 doi: 10.1111/dme.12700
    CrossrefPubMedGoogle Scholar
  • 29 Brophy S, Davies H, Mannan S. et al. Interventions for latent autoimmune diabetes (LADA) in adults.. Cochrane Database Syst Rev 2011; CD006165 doi: 10.1002/14651858.CD006165.pub3
    Google Scholar
  • 30 Stenstrom G, Gottsater A, Bakhtadze E. et al. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment.. Diabetes 2005; 54 (02) S68-S72 doi: 10.2337/diabetes.54.suppl_2.S68
    CrossrefPubMedGoogle Scholar
  • 31 Hwangbo Y, Kim JT, Kim EK. et al. Prevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic acid decarboxylase antibody.. Diabetes Metab J 2012; 36: 136-143 doi: 10.4093/dmj.2012.36.2.136
    CrossrefGoogle Scholar
  • 32 Buzzetti R, Di Pietro S, Giaccari A. et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes.. Diabetes Care 2007; 30: 932-938 10.2337/dc06-1696
    CrossrefGoogle Scholar
  • 33 Hawa MI, Kolb H, Schloot N. et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7.. Diabetes Care 2013; 36: 908-913 doi: 10.2337/dc12-0931
    CrossrefGoogle Scholar
  • 34 Hawa MI, Buchan AP, Ola T. et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes.. Diabetes Care 2014; 37: 1643-1649 doi: 10.2337/dc13-2383
    CrossrefPubMedGoogle Scholar
  • 35 Pham MN, Hawa MI, Pfleger C. et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4.. Diabetologia 2011; 54: 1630-1638 doi: 10.1007/s00125-011-2088-6
    CrossrefGoogle Scholar
  • 36 Pham MN, Hawa MI, Roden M. et al. Increased serum concentrations of adhesion molecules but not of chemokines in patients with type 2 diabetes compared with patients with type 1 diabetes and latent autoimmune diabetes in adult age: action LADA 5.. Diabet Med 2012; 29: 470-478 doi: 10.1111/j.1464-5491.2011.03546.x
    CrossrefGoogle Scholar
  • 37 Hansen MP, Matheis N, Kahaly GJ. Type 1 diabetes and polyglandular autoimmune syndrome: a review.. World J Diabetes 2015; 6: 67-79 doi: 10.4239/wjd.v6.i1.67
    CrossrefPubMedGoogle Scholar
  • 38 Kakleas K, Soldatou A, Karachaliou F. et al. Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM).. Autoimmun Rev 2015; 14: 781-797 doi: 10.1016/j.autrev.2015.05.002
    CrossrefGoogle Scholar
  • 39 Kim SH. Maturity-onset diabetes of the young: what do clinicians need to know?. Diabetes Metab J 2015; 39: 468-477 doi: 10.4093/dmj.2015.39.6.468
    CrossrefGoogle Scholar
  • 40 Lowe LP, Metzger BE, Dyer AR. et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations of maternal A1C and glucose with pregnancy outcomes.. Diabetes Care 2012; 35: 574-580 doi: 10.2337/dc11-1687
    CrossrefGoogle Scholar